Laninamivir Octanoate

CHEMBL467058 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
472.5 g/mol
LogP
0.4
Phase
4

This inhaled prodrug is converted in lung tissue to laninamivir, a long-acting neuraminidase inhibitor that blocks influenza viruses from spreading between cells. A single dose is intended to provide treatment for influenza, making it potentially more convenient than multi-day treatment regimens.

Khối lượng phân tử

472,5000 g/mol

LogP

0,40

TPSA

196,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCCCC(=O)OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(=O)O)=C[C@H](NC(=N)N)[C@H]1NC(C)=O

InChI

InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1

Molecular Formula

C21H36N4O8

HBD / HBA

5 / 9

Liên kết có thể quay

15

Nguyên tử nặng

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This inhaled prodrug is converted in lung tissue to laninamivir, a long-acting neuraminidase inhibitor that blocks influenza viruses from spreading between cells. A single dose is intended to provide treatment for influenza, making it potentially more convenient than multi-day treatment regimens.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Laninamivir Octanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL467058. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9847629. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.